🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  2. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    previously untreated chronic lymphocytic leukemia (CLL)

    phase 2 small molecule active

    1 trial

  3. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    B-cell Malignancy

    phase 2 small molecule active

    3 trials

  4. BGB-A317

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  5. BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 2 small molecule active

    1 trial

  6. BI 1744 CL 2 µg

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  7. BI 1810631

    Boehringer Ingelheim

    HER2-mutated or overexpressed/amplified solid tumours

    phase 2 small molecule active

    1 trial

  8. BI 1815368, BI 1815368 Placebo, BI 1815368

    Boehringer Ingelheim

    Centre-involved diabetic macular edema

    phase 2 small molecule active

    1 trial

  9. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  10. BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  11. BI 3000202, BI 3000202, Placebo matching BI 3000202

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  12. BI 3720931, BI 3720931

    Boehringer Ingelheim

    Cystic fibrosis

    phase 2 small molecule active

    1 trial

  13. BI 3720931, Gadovist 1.0 mmol/ml solution for injection, Solvent for dilution for BI 3720931 inhaler solution, BI 3720931

    Boehringer Ingelheim

    Cystic fibrosis

    phase 2 small molecule active

    1 trial

  14. BI 655130

    Boehringer Ingelheim

    Dermatitis, Atopic

    phase 2 small molecule completed

    1 trial

  15. BI 671800

    Boehringer Ingelheim

    Asthma

    phase 2 small molecule completed

    1 trial

  16. BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374

    Boehringer Ingelheim

    clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease

    phase 2 small molecule active

    1 trial

  17. BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

    Boehringer Ingelheim

    chronic kidney disease

    phase 2 small molecule active

    1 trial

  18. BI 764198

    Boehringer Ingelheim

    Proteinuric Kidney Diseases

    phase 2 small molecule active

    1 trial

  19. BI 764198, Placebo to match BI 764198, BI 764198, BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 2 small molecule active

    1 trial

  20. BI 764524, Sham Injection Procedure

    Boehringer Ingelheim

    Diabetic retinopathy

    phase 2 small molecule active

    1 trial

  21. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim

    Solid tumours

    phase 2 small molecule active

    1 trial

  22. BI-754091 plus afatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule completed

    1 trial

  23. BIIB122 225 mg

    Denali Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  24. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources